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Abstract: Vitamin A is an essential micronutrient throughout life. Its physiologically active
metabolite retinoic acid (RA), acting through nuclear retinoic acid receptors (RARs), is a potent
regulator of patterning during embryonic development, as well as being necessary for adult tissue
homeostasis. Vitamin A deficiency during pregnancy increases risk of maternal night blindness
and anemia and may be a cause of congenital malformations. Childhood Vitamin A deficiency can
cause xerophthalmia, lower resistance to infection and increased risk of mortality. RA signaling
appears to be essential for expression of genes involved in developmental hematopoiesis, regulating
the endothelial/blood cells balance in the yolk sac, promoting the hemogenic program in the
aorta-gonad-mesonephros area and stimulating eryrthropoiesis in fetal liver by activating the
expression of erythropoietin. In adults, RA signaling regulates differentiation of granulocytes and
enhances erythropoiesis. Vitamin A may facilitate iron absorption and metabolism to prevent anemia
and plays a key role in mucosal immune responses, modulating the function of regulatory T cells.
Furthermore, defective RA/RARα signaling is involved in the pathogenesis of acute promyelocytic
leukemia due to a failure in differentiation of promyelocytes. This review focuses on the different
roles played by vitamin A/RA signaling in physiological and pathological mouse hematopoiesis
duddurring both, embryonic and adult life, and the consequences of vitamin A deficiency for the
blood system.
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1. Introduction
Vitamin A was discovered in the second decade of the twentieth century by Elmer McCollum and
Marguerite Davis [1]; also known as retinol, it is one of the fat soluble vitamins, and plays an important
role in vision, reproduction, immune function, as well as cell growth and communication [2–10].
Vitamin A, regarded as an important micronutrient in mammalian diet, exists in three forms: retinal,
retinol and retinoic acid (RA), the latter being the most metabolically active. Dietary vitamin A
is obtained from plant sources (provitamin A carotenoids, particularly β-carotene) or as retinyl
esters from animal sources, fortified food products and supplements. The metabolic fate of this
retinol is the esterification and tissue storage (primarily in the liver), or the irreversible oxidation to
all-trans retinaldehyde and to all-trans retinoic acid (ATRA) by alcohol and aldehyde deshydrogenases.
In mammals, this latter family of enzymes includes three cytosolic aldehyde dehydrogenases: RALDH1
(encoded by the ALDH1A1 gene) [11], RALDH2 (ALDH1A2), which is the main RA-synthesizing
enzyme in the mesoderm [12], and RALDH3 (ALDH1A3) [13–15].
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RA signaling is mediated by two families of nuclear receptors: RARs and RXRs, including three
members α, β and γ for each family [16]. Nuclear retinoid receptors are frequently composed of
RXR and RAR heterodimers, although RXRs can form homodimers or heterodimers with other
nuclear receptors such as the vitamin D receptor, as discussed below, or PPARs (peroxisome
proliferator-activated receptors). In the nucleus, the RAR/RXR complex is bound to a specific sequence
of DNA (RARE: retinoic acid response element) and usually performs repressor roles in the absence of
ligands, activating transcription of target genes when bound to them ([16,17]) (Figure 1).
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Figure 1. Role of vitamin A/retinol in adult hematopoiesis. This picture shows the main molecular 
pathways leading from the vitamin A sources to the target genes of the retinoic acid (RA, the active 
form of vitamin A) related with hematopoiesis in the tissues. Retinol or provitamin A is ingested and 
absorbed through the intestine, transported by retinol‐binding proteins and stored in the liver. Retinol 
is transformed by the cells into RA by alcohol and aldehyde dehydrogenases (ADHs and RALDHs 
respectively). RA  is  transported by  cellular  retinoic acid binding proteins  (CRABP) and  it  can be 
degraded by CYP26 or translocated to the nucleus, where it binds and activates nuclear retinoid acid 
receptors (RARs and RXRs), displacing co‐repressors and recruiting coactivators of the transcription 
of target genes. In this way, RA regulates the developmental hematopoiesis, modulates lympho and 
granulopoiesis and contributes to the homeostasis of the hematopoietic stem cells. Vitamin D receptor 
(VDR) can also dimerize with RXRs and modulate the immune response.   
Vitamin A  deficiency  is widespread  in  developing  countries  [8].  Besides  prominent  ocular 
consequences of this deficiency (e.g., xerophthalmia), anemia and immune deficiency highlight other 
critical roles of vitamin A/RA signaling [5,6]. Furthermore, RA signaling is crucially involved in the 
pathogenesis but also in the treatment of some types of leukemia [18,19]. For these reasons, in this 
review we aim  to provide  the  readers with an update on  the  functions played by vitamin A/RA 
signaling in the development, homeostasis and pathology of the hematopoietic system. An earlier 
report  of  our  group  mainly  focused  on  the  functions  of  RA  signaling  for  developmental 
Figure 1. Role of vitamin A/retinol in adult hematopoiesis. This picture shows the main molecular
pathways leading from the vitamin A sources to the target genes of the retinoic acid (RA, the active
form of vitamin A) related with hematopoiesis in the tissues. Retinol or provitamin A is ingested and
absorbed through the intestine, transported by retinol-binding proteins and stored in the liver. Retinol
is transformed by the cells into RA by alcohol and aldehyde dehydrogenases (ADHs and RALDHs
respectively). RA is transported by cellular retinoic acid binding proteins (CRABP) and it can be
degraded by CYP26 or translocated to the nucleus, where it binds and activates nuclear retinoid acid
recep o s (RARs and RXRs), displacing co-repressors and recruiting coactivat rs of the transcription
of target genes. In this way, RA regulates the developmental hema opoiesis, modulates lympho and
granulopoiesis an contributes to the home stasis of the hematopoietic stem cells. Vitamin D receptor
(VDR) can also dimerize with RXRs and modulate the immune response.
Vitamin A deficiency is widespread in developing countries [8]. Besides prominent ocular
consequences of this deficiency (e.g., xerophthalmia), anemia and immune deficiency highlight other
critical roles of vitamin A/RA signaling [5,6]. Furthermore, RA signaling is crucially involved
in the pathogenesis but also in the treatment of some types of leukemia [18,19]. For these
reasons, in this review we aim to provide the readers with an update on the functions played by
vitamin A/RA signaling in the development, homeostasis and pathology of the hematopoietic system.
An earlier report of our group mainly focused on the functions of RA signaling for developmental
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hematopoiesis [20]. In this review, mainly focused on the mouse model, we pay more attention to
essential roles played by vitamin A in the hematopoietic system.
2. Vitamin A/Retinoic Acid in Developmental Hematopoiesis
RA signaling plays an essential role in vascular development and in the early embryonic
hematopoiesis. In the mouse embryo, hematopoiesis starts around E7.0–E7.5, when a first generation
of primitive erythroid cells and endothelial cells forms clusters or blood-islands in the splanchnic
mesoderm of the yolk sac. Later, these clusters connect with the developing vessels of the embryo.
These primitive erythroid cells are soon replaced by a second wave of hematopoiesis, when
hematopoietic progenitors and the definitive hematopoietic stem cells (HSC) arise from hemogenic
endothelial cells [21–23]. This second wave gives rise to different blood cell lineages and originates
sequentially in precise mesodermal domains of the mouse embryo, the yolk sac first, by E8.5, the
placenta by E9.5 and finally in the aorta-gonad-mesonephros (AGM) area by E10.5 [24,25]. Later, about
E11–E12, the fetal liver becomes the main site for embryonic hematopoiesis, receiving progenitors
from the mesodermal domains quoted above and allowing for their expansion. The HSC and the
hematopoietic activity finally move to the bone marrow shortly before birth [26,27]. As follows, we
will describe how signaling by RA acts in the main hematopoietic sites: yolk sac, AGM, fetal liver and
placenta (Figure 2).
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by vitamin A/RA  signaling  are described  between parentheses. Black  arrows  represent  the main 
routes  of migration  of  progenitors  between  the  hematopoietic  organs  and  tissues.  Exchange  of 
progenitors  between  embryonic  organs  is  also  possible.  It  is  unknown  if RA  signaling  plays  an 
intrinsic role on placental hematopoietic stem cells (HSC). AGM: Aorta‐Gonad‐Mesonephros. 
2.1. Yolk Sac 
RA signaling is involved in the differentiation of the endothelium, as well as in the emergence 
of the hematopoietic progenitors [28]. The embryonic endothelium of the yolk sac expresses RARα, 
and  this  expression  is  prominent  in  FLK1+/c‐KIT+/CD45−  cells  that  represent  the  hemogenic 
endothelium [29].   
RALDH2 is expressed in visceral endoderm and generates RA, which activates the RARs of the 
visceral mesoderm. The lack of RA in RALDH2 knockout mice leads to death at E10.5 due to multiple 
Figure 2. Hematopoietic sites in the e bryo (left) and adult mouse (right). The main functions played
by vitamin A/RA signaling are described between parentheses. Black arrows represent the main routes
of migration of progenitors between the hematopoietic organs and tissues. Exchange of progenitors
between embryonic organs is also possible. It is unknown if RA signaling plays an intrinsic role on
placental hematopoietic stem cells (HSC). AGM: Aorta-Gonad-Mesonephros.
2.1. Yolk Sac
RA signaling is involved in the differentiation of the endothelium, as well as in the emergence of
the hematopoietic progenitors [28]. The embryonic endothelium of the yolk sac expresses RARα,
and this expression is prominent in FLK1+/c-KIT+/CD45− cells that represent the hemogenic
endothelium [ 9].
RALDH2 is expressed in visceral endoderm and gen rate RA, w ich activat s the RARs of
the visceral mesoderm. The lack of RA in RALDH2 knockout mice leads to death at E10.5 due to
multiple defects, including disorganization of yolk sac extraembryonic vascular network [29–32] and
Nutrients 2017, 9, 159 4 of 18
downregulation of hematopoiesis-related genes (such as GATA1/2, SCL/TAL1, LMO2 and RUNX1)
by the hemogenic endothelium [29]. These developmental defects in the RALDH2 mutants can be
rescued with exogenous RA treatment in vivo and in embryo culture [29,32].
2.2. Aorta-Gonad-Mesonephros (AGM)
As well as in the yolk sac, RA signaling in AGM is essential for emergence of hematopoietic
progenitors, including definitive HSC, from the hemogenic endothelium of the dorsal aorta. RALDH2
is expressed in coelomic mesothelium at E9.5 and later in mesenchymal cells of AGM region (Figure 3).
Activation of RA signaling pathway enhances the generation of HSCs in both isolated hemogenic
endothelial cells and pre-HSCs. In addition, conditional deletion of RALDH2 in endothelium (using
a VE-CadherinCre/RALDH2flox system) precludes the HSC formation in yolk sac and dorsal aorta,
demonstrating that the endothelium itself is a main source of RA. These authors also demonstrated
that the RA signal for the endothelial-hematopoietic transition is transduced through RARα, a receptor
highly expressed in the endothelium [33]. However, the RARα knockout mice do not show an abnormal
phenotype, likely due to a compensation of its function by other RA receptors [34,35].
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(IM) (arrows in A) by the stage E9.5 (A) and later (B) in mesenchymal cells of area, where the definitive 
population of hematopoietic stem cells is generated, between the aorta (AO), the cardinal veins (CV) 
and  the gonadal/mesonephric mesoderm  (G‐M). This embryonic RA  signaling  is  essential  for  the 
emergence of the definitive blood progenitors, as described in the text. M: mesentery; NT: neural tube.   
RA signaling is also involved in the regulation of endothelial cell cycle and the specification of 
the hemogenic endothelium [28]. The c‐KIT expression by the hemogenic endothelium (cell surface 
Figure 3. Vitamin A in developmental hematopoiesis. The picture shows immunolocalization of
the enzyme RALDH2, catalyzing a key step in the generation of retinoic acid from retinol in the
aorta-gonad-mesonephros. RALDH2 is expressed in the coelomic epithelium of the intermediate
mesoderm (IM) (arrows in A) by the stage E9.5 (A) and later (B) in mesenchymal cells of area, where
the definitive population of hematopoietic stem cells is generated, between the aorta (AO), the cardinal
veins (CV) and the gonadal/mesonephric mesoderm (G-M). This embryonic RA signaling is essential
for the emergence of the definitive blood progenitors, as described in the text. M: mesentery; NT:
neural tube.
RA signaling is also involved in the regulation of endothelial cell cycle and the specification of
the hemogenic endothelium [28]. The c-KIT expression by the hemogenic endothelium (cell surface
marker of hematopoietic precursors) is downregulated in RALDH2 deficient mouse embryos while
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RUNX1, a hematopoietic stem cell transcription factor, is upregulated. This leads to endothelial
hyperproliferation and an impaired hemogenic endothelium, a phenotype very similar to the one
resulting of NOTCH signaling inhibition. It has been proposed that the RA/c-KIT/NOTCH axis
regulates the endothelial cell cycle and the specification of the hemogenic endothelium whereas RUNX1
regulates the generation and/or propagation of multilineage HSC from the hemogenic endothelial
cells [36].
2.3. Fetal Liver
Fetal liver HSCs probably require RA signaling for induction of HOXA medial gene expression
and control of HSC identity and function, as suggested by experiments with human embryonic stem
cells and fetal liver HSC [37]. Incidentally, HOXA cluster genes, which are targets of RA signaling,
regulate proliferation of adult mouse HSC [38].
RA signaling has a role in the erythropoiesis from the fetal liver. Erythropoietin (EPO) is a
glycoprotein hormone produced by the kidney and promotes the formation of red blood cells by
the bone marrow. The early wave of erythropoiesis in the yolk sac is EPO independent; however,
the early phase of fetal liver erythropoiesis requires EPO, retinoic acid signaling through RAR/RXR
receptors and also stabilization of the hypoxia inducible factor (HIF1). Interestingly, RXRα requirement
is only active during this early phase (E9.5–E11.5), as erythropoiesis can continue without RXRα
signaling from E12 on. In fact, EPO expression is 10 folds lower in RXRα-/- fetal liver than in controls
at E10, but there are no differences at E12. Other elements of the retinoic signaling pathway, such as
RALDH1/2, cellular retinol-binding protein-1 (CRBP1) and cellular retinoic acid-binding protein-1
and 2 (CRABP1/2) are highly expressed in the early fetal liver, when the hematopoiesis is taking place,
and are downregulated by midgestation, suggesting that they may play a role in hematopoiesis [39].
2.4. Placenta and Umbilical Cord
Hematopoiesis in the placental labyrinthine zone and umbilical arteries has been well described
throughout development [22,40–46]. The retinoic acid receptor RXRα is strongly expressed in the
developing labyrinthine zone of the chorioallantoic placenta. Inactivation of this receptor causes
disorganization of the labyrinthine zone, abnormal stasis of maternal blood and a disruption of the
network of embryonic vessels and maternal sinuses [47]. RXRα-/-/RXRβ-/- double mutant embryos
die between E9.5 and E10.5 due to a lack of formation of the labyrinthine zone [48]. However, a direct
requirement of RA signaling on placental hematopoiesis has not been described, but it cannot be
discarded. A population of hemogenic precursors expressing endothelial and early hematopoietic
markers is localized in the vascular labyrinth where RA/RXR signaling is critical [49]. Thus, more
studies will be necessary to know if RA plays a role in placental/umbilical cord hematopoiesis as it
happens in other embryonic territories.
2.5. Vitamin A/Retinoic Acid and Developmental Hematopoiesis in Zebrafish
The zebrafish (Danio rerio) is a powerful animal model to study the role of RA during development.
Some recent reports have shown that RA signaling is critical in early steps of zebrafish hematopoiesis,
including the formation of the HSCs. RA signaling is required for HSC marker expression even before
the formation of the aorta, when the main RA synthesis enzyme, RALDH2, is expressed in the paraxial
mesoderm. This requirement is related with the expression of junctional adhesion molecules JAM1a
and JAM2a (which are essential for proper transduction of Notch signals), the chemokine CXCL12 and
its main receptor CXCR4 [50].
Later, RA signaling is involved in the generation of a first wave of erythrocytes and myeloid cells,
but playing in this case an inhibitory role. This primitive wave of hematopoiesis is strongly reduced
by treatment with exogenous RA at the 5 somite stage, while expression of the vascular marker FLI1 is
increased. This effect can be rescued by injection of mRNA of the hematopoietic transcription factor
SCL. Inhibition of the enzyme RALDH2 by 4N-diethylaminobenzaldehyde (DEAB) treatment leads
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to increased expression of GATA1-expressing erythroid cells [51,52]. Primitive myelopoiesis is also
restricted by RA before 11 hpf (hours post fertilization). Interestingly, GATA4/5/6-depleted zebrafish
embryos show deficient primitive myelopoiesis but this phenotype can be rescued by DEAB treatment
or RALDH2 knockdown. Thus, GATA4/5/6 are negative regulators of RA signaling, while RA inhibits
commitment of mesodermal cells to hematopoietic fates upstream SCL [53].
3. Vitamin A/Retinoic Acid in Adult Hematopoiesis
Vitamin A (Retinol) and its derivatives (retinoids) play a key role in development and are
important in the homeostasis of many organs in adults [16].
The receptors RARα and γ, but not the RARβ receptor, are highly expressed in the adult
hematopoietic system. RARα is expressed in a variety of bone marrow cells, while RARγ is expressed
in primitive hematopoietic progenitors, a deficiency of which causes a reduction in the number of
HSC [54]. Loss of function of RARα and γ results in viable mice with reduced lifespan [34,35].
RARα-/- mice show no defects in the early steps of adult hematopoiesis and this receptor is not
involved in the self-renewal potential of HSC. However, RA signaling transduced through RARα
is critically required for granulocytic lineage modulation. The presence of free RARα receptor not
bound to RA inhibits neutrophil differentiation while the binding of RA induces its differentiation [55].
However, overexpression of RARα increases the number of granulocytes while overexpression of
RARγ induces increase of undifferentiated progenitors [54].
RARγ-/- mice are anemic [56] and develop myeloproliferative syndrome, likely by a defective
function of RARγ in the bone marrow cellular niche [57]. The erythropoiesis is normal after conditional
deletion of RARα and RARγ in adult cells expressing the EPO receptor (EPOR), indicating that RARγ
is playing a function in cells other than erythroid progenitors [56]. NOTCH and HOXB4 are known
regulators of HSC self-renewal [58,59]; while HOXB4 expression in HSC is normal in the RARγ
mutants, NOTCH1 and its effector HES1 are both downregulated [54].
In contrast, it has been demonstrated that RARγ regulates B and T lymphopoiesis in the thymus
and bone marrow. It was initially described that RARγmutants only display defective primary and
memory CD8+ T cell response, and the production of inflammatory cytokines by macrophages appears
impaired [60]. However, the conditional deletion of this receptor in nestin-expressing stromal cells
leads to a decrease in the number of circulating B and CD4+ T cells demonstrating that RARγ receptor
expression in the bone marrow and thymus microenvironment is required for lymphopoiesis [61].
In humans, the RA/RAR signaling system also plays a key role in the balance between self-renewal
and differentiation in the bone marrow niche. Bone marrow human primitive CD34+/CD38− HSC
express RALDH1 and RARα. The inhibition of the RA signaling on cultured HSC induces HOXB4
upregulation, which prevents their differentiation and enhances their proliferation and expansion in
an undifferentiated stage [62]. RA degradation by the enzyme CYP26 from stroma could be involved
in this mechanism, contributing to the maintenance of the pool of self-renewing HSCs. On the other
hand, pharmacological inhibition of aldehyde dehydrogenases with DEAB allows for expansion of
HSC in culture, preventing their differentiation. Treatment with retinoids and vitamin D abolishes
this effect [63]. However, when human HSC are cultured with RARα antagonists, the lifespan of the
cultures, the number of the progenitors and also the production of monocytes and neutrophils increase,
while antagonists of RARγ do not affect the cultures [64]. This specific role of RARα for human HSC
would be different to that above described in mice.
RA/RARα signaling is also essential for lymphocyte function and plays a key role in the regulation
of the immune homeostasis, the differentiation of T cell subsets, the migration of T cells into tissues,
and the development of T cell-dependent antibody responses [65–67]. In the intestine, RA is produced
by gut-associated dendritic cells and is required for generating gut-associated lymphocytes [68].
Migration of innate lymphoid cells to the intestine is induced by changes in the homing receptors
regulated by mucosal dendritic cells and RA signaling [69,70]. These effects of vitamin A/RA signaling
on T cell biology account for the central role played by this micronutrient in immunity [71].
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RA also modulates proliferation and differentiation of B cells [72,73]. RA signaling, together with
Toll-like receptor 9 (TLR9) ligands, protect B lymphocytes against damage-induced apoptosis through
the increase of the expression of the myeloid cell leukemia-1 protein. Importantly, this protective
effect was not observed in malignant B cells, thus suggesting that RA+TLR9 ligands could be useful in
treatment of B-cell malignancies by selectively protecting non-malignant B cells [74].
4. RA and Leukemia
The role played by RARα in modulation of the granulocyte differentiation above described is
related with the pathogeny of acute promyelocytic leukemia (APL). This disease is produced by a
chromosomal rearrangement, where the RARα gene fuses with other genes and generate a dominant
defective form of RARα. Lack of RA signaling through the RARα receptor results in blockage of
promyelocytic progenitors’ differentiation. The most frequent translocation is the fusing of the PML
gene, which codes for the promyelocytic leukemia protein, a tumor suppressor transcription factor,
with the RARα gene, although up to eight genes more have been identified in these translocations [18].
The treatment of APL with all trans-retinoic acid (ATRA) combined with arsenic trioxide (As2O3,
ATO) has improved dramatically the prognostic of this disease, lethal some decades ago, and currently
cured in about 95% of the cases [19,75–78]. The National Comprehensive Cancer Network has adopted
ATRA and ATO as first-line treatments for APL in its 2014 guidelines [79]. For non-high-risk APL
patients treatment with RA+ATO without chemotherapy resulted in 2-year overall survival rates
of 99% [80]. A recent trial showed 7-year survival rates above 90% when arsenic and ATRA were
used as first-line target treatments (with chemotherapy for consolidation) [81]. Other clinical trials in
non-high-risk patients are also promising [82,83]. For a review on ATRA/ATO treatment in high-risk
patients see Norsworthy and Alman [84].
Acute myeloid leukemia (AML) is a disease characterized by accumulation of myeloid blasts
in the bone marrow, blood and other tissues, which lack the ability to differentiate, consequently
causing a decreased production of normal blood cells [85]. A number of synthetic or natural products
are being assayed in preclinical studies to further improve the beneficial effect of the ATRA/ATO
treatments [78,86–88]. The effect of HER2/ERBB2 inhibitor, TAK165, can be emphasized, which
synergizes with ATRA, thus leading to improved differentiation of AML cells, which are normally
resistant to RA treatment. HER2 is the epidermal growth factor receptor 2, which plays a critical role
in the regulation of mammalian cell survival, proliferation and differentiation [89].
Despite these excellent therapeutic outcomes, treatment of leukemia with ATRA can produce
inflammatory reactions in about 25% of patients. These adverse reactions are known as differentiation
syndrome, previously known as ATRA syndrome, and it is characterized by fever, peripheral edema,
pleuropericardial effusion, respiratory distress, hypotension and renal/hepatic dysfunction [90]. The
differentiation syndrome is caused by release of inflammatory cytokines and it requires a preventive
strategy based in corticosteroid treatment [91].
The molecular pathways leading to differentiation of APL cells induced by ATRA are being
unveiled by studies in vitro. RA induces a neutrophil-like phenotype in HL-60 leukemia cells [92]
and increases their differentiation [93]. Differentiation of NB4 cells, a maturation inducible cell line
isolated from human acute promyelocytic leukemia, requires RAF1/MEK/ERK signaling involved in
ATRA-induced differentiation in APL cells through enhancing the protein level of C/EBPβ, C/EBPε
and PU.1 [94]. Additionally, ATRA inhibits HOXA7 in NB4 cells [95]. HOXA5 is upregulated by
ATRA in K562 human myeloid leukemia cell line, provoking apoptosis and inhibition of cell cycle [96].
However, function of HOX cluster genes in leukemia cells is very complex, as demonstrated by the
decreased proliferation and increased apoptosis reported in pro-monocyte U937 cells, when HOXA5 is
downregulated by shRNA [97].
Other applications of RA have been reported in immunotherapy of T cell leukemia. ATRA,
combined with interferon-α, upregulate CD38 in malignant cells, rendering them sensitive to a
chimeric anti-CD38 antibody [98].
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5. Epigenetic Modulation of Hematopoiesis by Vitamin A/RA
As described above, vitamin A/RA signaling exerts their regulation on hematopoietic processes
through the transcriptional activity of the RAR and RXR receptors. However, epigenetic mechanisms
also regulate hematopoiesis (reviewed in Shashida and Iwama, [99]) and are also involved in
hematopoietic malignancies. Chimeric oncoproteins generated by chromosomal translocations,
as described above, can induce chromatin alterations on target genes by aberrant deployment
of enzymes, such as DNA methyltransferases and histone acetyltransferases, deacetylases and
methyltransferases [100,101]. For example, an epigenetic modification mediates ATRA resistance
in AML cells. The most common acute myeloid leukemia-associated fusion protein, AML1/ETO,
forms a complex with RARα and promotes a repressed chromatin conformation at the RARβ2
regulatory regions. In fact, the treatment with the DNA methylation inhibitor 5-azacytidine, reverts
this alteration and restores the differentiation response induced by ATRA treatment in the same
way as the knockdown of the AML1/ETO expression [102]. Thus, lysine-specific demethylase-1
(LSD1), an enzyme responsible for demethylation of histone H3, represents a promising pharmacologic
approach for AML therapy-enhancing response to ATRA treatment, and as a consequence, clinical
trials are being currently performed in this direction [103].
One percent of APL cases are due to a translocation fusing the promyelocytic leukemia zinc finger
(PLZF) gene with the RARα gene. These APL are refractory to ATRA treatment. PLZF represses
the CRABPI locus (encoding cellular retinoic acid binding protein I) by an epigenetic mechanism
involving chromatin condensation [104]. As well, PLZF-RARα interacts with histone deacetylase
corepressors promoting epigenetic silencing of the cell cycle regulator p21/CDKN1A, resulting in
increased proliferation [105,106]. Incidentally, p21 expression is activated by retinoic acid through a
RARE in the CDKN1A promoter [106].
Myelofibrosis with myeloid metaplasia (MMM) is another hematopoietic malignancy related with
RA signaling and its epigenetic regulation. Expression of RARβ2 is downregulated in CD34+ cells
from MMM patients, but only in 25% allelic loss has occurred due to a 3p24 chromosomal deletion.
Instead, hypermethylation of RARβ2 locus was found in most MMM patients but not in normal
individuals [107]. This RA receptor was mentioned above as mediator of the ATRA resistance in
AML1/ETO myeloid leukemia, where it is also repressed by epigenetic mechanisms.
Finally, miRNAs post-transcriptional regulation in hematopoietic cells can also play a role
in retinoid-based treatment of leukemia. For example, regulation by miR-223 is essential for
ATRA-induced differentiation of acute promyelocytic leukemia (APL) blasts to granulocytes [108].
6. Vitamin A/Vitamin D Interrelationships in Hematopoiesis and Leukemia
As stated in the introduction, RXRs can form heterodimers with the vitamin D receptor (VDR).
In this way, physiological functions mediated by vitamin D, via the binding of its active metabolite
1α,25-dihydroxyvitamin D3, are closely related to retinoid signaling and this modulation is relevant
for hematopoiesis and also for AML treatment, as described below. Vitamin D enhances binding of
RXR/VDR heterodimer to vitamin D response elements and it restricts the ability of 9-cis-RA to signal
through the RXRα receptor, modulating the retinoid signaling pathway [109,110].
Vitamin D signaling seems to be dispensable for hematopoiesis, since vitamin D signaling-deficient
mice show no phenotype related with blood cells production [111–113]. However, this signaling
pathway does play a role in modulating this process (reviewed in Bunce et al. [114]) [115], as well as the
immune response [112,116–118]. Treatment of hematopoietic stem cells or some leukemia cell lines with
the active form of the vitamin D leads to increased monocyte/macrophage differentiation [92,119,120],
an effect which is not detected in VDR knock-out mice [114,119]. As stated above, when cultured HSC
are treated with RA signaling inhibitors, their differentiation is blocked, but retinoids and vitamin D
treatment counteract this effect [64]. Since RARα receptor activation induces granulopoiesis, it has
been suggested that VDR and RARα can compete for RXR heterodimerization. In this way, VDR/RXR
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and RAR/RXR heterodimers would drive differentiation of progenitors towards monopoiesis and
granulopoiesis, respectively [115,119].
ATRA treatment is ineffective for AML, as stated above. Since vitamin D3 induces monocytic
differentiation of some lines of leukemic cells, vitamin D analogs could represent a therapeutic
option [115,119,121]. Synergy between vitamin D and RA signaling is demonstrated by the enhanced
neutrophil differentiation of NB4 cells when a RARα agonist (AGN195183) is used in combination
with a low concentration (10 nM) of vitamin D3 [64]. The differentiation effect of the RA/vitamin D3
combination is variable in different AML cell lines [122], and this is probably due to the regulation
of the VDR transcription by RARα. High levels of RARα protein repress the VDR gene in absence of
RARα agonists [123].
7. Vitamin A Deficiency and Anemia
Given the role played by vitamin A/RA signaling in hematopoiesis, it seems clear that vitamin A
deficiency (VAD) must constitute a serious problem for the functions of the blood system, and this
has been demonstrated in a number of animal models. In mice fed with a vitamin A deficient diet or
treated with RAR antagonists, an increase of myeloid cells is observed in bone marrow, spleen and
peripheral blood [124,125]. This effect leads to a severe splenomegaly in 14-week old mice after having
received a vitamin A-deficient diet from birth. This condition can be partially reverted by a vitamin A
supplemented diet. The frequency of myeloid progenitors (bone marrow CFUs) is not influenced by
the lack of RA, but the frequency of apoptosis in CD11b+/Ly-6G+ neutrophils cells is significantly
lower in vitamin A-deprived mice, probably explaining the increased myeloid cell population [124].
On the other hand, rats fed with a vitamin-A deficient diet show a significant decrease in serum iron,
transferrin receptor saturation and erythropoietin expression. At the same time, iron concentration
increased in the spleen, indicating ineffective erythropoiesis [126]. Furthermore, vitamin A is involved
in the regulation of iron-regulatory protein (IRP2), subsequently affecting iron metabolism. In this way,
iron deficiency is aggravated in rats under VAD conditions [127]. Interestingly, vitamin A induced
ferroportin-1 expression in Caco-2 cells, suggesting that RA signaling could support mobilization and
transport of iron from intestinal cells [128].
In humans, particularly in children and pregnant/lactating women, VAD has been recognized
as a public health issue in developing countries [129]. The estimated number of people in the world
that are affected by micronutrient deficiencies varies between 1 and 2 billion [8,130,131]. Adequate
Vitamin A intake is associated with a lower rate of overall morbidity among children [132,133]. VAD
(defined as serum retinol <20 µg/dL) is associated with decreased dietary supply of vitamin A and
its precursors [131]. An extensive survey of the global extent and importance of VAD is available
online [134,135]. Just to quote some facts, an estimated 250 million preschool children suffer from VAD
globally. In low-income countries, 10% to 20% of pregnant women develop VAD [136].
Severe VAD leads to xerophthalmia, the most common cause of preventable blindness among
children. According to WHO data, 250,000 to 500,000 vitamin A-deficient children become blind
every year, half of them dying within 12 months of losing their sight [134]. VAD is also associated
with increased risk of death from severe infections [129,137,138]. VAD is also related with anemia,
probably through its role in mobilization and transport of iron [139], as suggested by experiments in
animal models quoted above [127,128]. Although iron deficiency is the dominant cause of nutritional
anemia, simultaneous use of iron and vitamin A supplements seems to be more effective to prevent
anemia than the use of either micronutrients alone, a fact that emphasizes the need of studies on the
interaction between these micronutrients, especially regarding iron absorption and erythropoiesis
modulation [130].
The beneficial effects of vitamin A or β-carotene supplements to prevent conditions derived from
VAD have been described in a number of papers. Just to mention some instances, biscuits fortified with
vitamin A reduced VAD and anemia in Chinese pre-school children [140]. Supplement of vitamin A to
women from preconception to lactation in rural Nepal showed that adolescent offspring developed
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higher levels of circulating antibodies than the control group [141]. This vitamin A treatment also
increased circulating hemoglobin during pregnancy, probably by increased insulin-like growth factor-1
(IGF-1), which has functions in erythropoiesis [142]. In Ethiopia, a single high dose of vitamin A
(30–60 mg) in children leads to modest increases (1.5 g/L) of circulating hemoglobin six months later,
reducing 9% the risk of anemia [143]. Finally, multiple micronutrients in powder (including vitamin A)
administered to young Brazilian RA children effectively reduced anemia and improved growth and
micronutrient status [144].
A number of strategies can be followed for prevention of VAD, i.e., dietary diversification,
high-dose supplementation, conventional food fortification (with artificial additives), biofortification
(by conventional plant breeding) and genetic modification of crops [145]. Promotion of dietary
diversification through nutrition education programs is a sustainable strategy and it can cover multiple
micronutrient deficiencies. However, this strategy lacks of measurable endpoints, and bears issues of
affordability [146].
Supplementation with high doses of vitamin A periodically dispensed to children between six
months and five years of age have demonstrated to be associated with large reductions in mortality,
morbidity, and vision problems in an extensive meta-analysis [137]. This conclusion was partially
challenged by the DEVTA cluster randomized trial developed in India, where the reduction in mortality
by vitamin A supplementation was lower than expected [147]. This result generated a controversy
that still continues [137,148–150] although periodic vitamin A supplementation seems to be safe and
effective considering globally the published reports.
Fortification of sugar, vegetable oils and cereal-based products by addition of vitamin A has been
extensively explored for VAD control in developing countries, having already provided good results
in Central and South America [150].
Biofortification of maize by conventional breeding (the “orange” maize) has been developed in
Zambia. Orange maize contains enhanced β-carotene concentrations and it appears to be as efficacious
as vitamin A supplementation in Zambian children [151,152]. Biofortification of cassava is currently
been assayed [153].
Finally, a strategy for fighting against VAD was the introduction of the “golden rice”, a transgenic
variety of rice that accumulates β-carotene in its endosperm [154]. Golden rice was created by Ingo
Potrykus as a humanitarian project and represents a promising strategy, but the criticisms from a
number of environmental and anti-GMO (genetically modified organisms) groups have obstructed
their test in humans [155].
8. Conclusions and Future Directions
In recent years, researchers have become increasingly interested in the multiple functions played
by vitamin A/RA signaling in developmental and adult hematopoiesis. This basic knowledge of the
molecular mechanisms modulated by RA signaling has led to impressive advances in the therapy of
some forms of leukemia, such as the APL. The induction of differentiation of malignant cells has been
possible by a better understanding of the cellular and molecular control by RA signaling of myeloid
differentiation. A major challenge for the near future will be to overcome the mechanisms of RA
resistance in the treatment of other types of leukemia. It will also be very important to advance in
the knowledge of the complex interrelationships between vitamin A/RA and vitamin D signaling,
particularly in processes related with the modulation of the immune response. Given the critical
importance of vitamin A/RA signaling in the immune defense and other essential processes for human
health, the fight against vitamin A deficiency is a priority in developing countries. More efforts will be
necessary to assess the current practices and to develop new, more effective and efficient strategies to
reduce the prevalence of this serious worldwide problem.
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